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httpcense.Abstract The aim was to investigate rosiglitazone and metformin effects on some vascular and bio-
chemical changes associated with streptozotocin (55 mg/kg; i.p.)-induced hyperglycaemia in rats. Iso-
lated aortas were used to evaluate their reactivity towards norepinephrine, acetylcholine, and sodium
nitroprusside. Blood samples were used to assess the biochemical changes of some parameters viz.,
plasma lipid peroxides and nitric oxide levels and erythrocytic glutathione peroxidase activity. Hyper-
glycaemic animals orally received rosiglitazone (0.5 mg/kg) or metformin (150 mg/kg) daily for
2 weeks and their effects were determined 24 h after the last dose. Our results revealed that streptozo-
tocin-induced hyperglycaemia is associated with impaired vascular reactivity towards various agents,
increased lipid peroxides level, decreased glutathione peroxidise activity, and decreased nitric oxide
level. Both drugs further decreased norepinephrine-induced contraction and improved acetylcholine-
and sodium nitroprusside-induced relaxations. Rosiglitazone restored the alterations in all tested bio-
chemical parameters while metformin restored only glutathione peroxidise activity. In conclusion
both drugs show beneﬁcial effects against the vascular dysfunction associated with hyperglycaemia
which might be related to their euglycaemic activity in addition to anti-oxidant property of rosiglitaz-
one and a direct effect of metformin on vascular smooth muscle.
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Diabetes mellitus (DM) is a group of metabolic diseases char-
acterized by chronic hyperglycaemia resulting from defects in
insulin secretion and/or insulin action. The chronic hyper-
glycaemia of diabetes is associated with long-term damage,
dysfunction, and failure of various organs, especially eyes,
kidneys, nerves, heart, and blood vessels.1,2 DM is among
the silent killers, since many people are not aware that they
have the disease until they develop one of its life-threateningaculty of Pharmacy, Cairo University.
.03.002
132 D.O. Saleh et al.complications. The prevalence of DM increases with age.3 DM
is associated with an increased risk of micro- and macrovascu-
lar complications, causing considerable morbidity and mortal-
ity.4 Blood glucose control can reduce the risk of these vascular
complications but does not prevent them altogether.5
Endothelial dysfunction, a non-traditional cardiovascular
risk marker, has been strongly associated with the reduced vas-
cular reactivity occurring in patients with type 2 DM, thereby
playing a major role in the development of complications of
the micro- and macrocirculation.6 Studies in experimental ani-
mals designed to investigate the mechanisms involved in such
vascular dysfunction have implicated various factors including
destruction of endothelial cells by oxidative stress and free rad-
icals that lead to altered release of endothelium-derived con-
stricting and relaxing factors.7
Nitric Oxide (NO) is an important endogenous regulator of
blood vessel tone by promoting vasodilatation and therefore it
plays an important role in the control of blood pressure (BP).8
It is generated from the amino acid L-arginine within healthy
endothelium by endothelial NO synthase (eNOS).9 Inefﬁcient
utilization of the substrate L-arginine by NOS and decreased
availability of NO due to scavenging by advanced glycated
end-products resulting from excessive hyperglycaemia have
been proposed to participate in impaired endothelial cell
function.10,11
There is considerable evidence that oxidative stress result-
ing from increased production and/or inadequate removal of
free radicals including reactive oxygen species (ROS) play a
key role in the pathogenesis of late diabetic complications.12
It has been reported that in uncontrolled diabetes, the levels
of endogenous anti-oxidants such as superoxide dismutase,
vitamin E, and lipoic acid are markedly reduced.13
The present study was devoted to investigate the inﬂuence
of 2 commonly used anti-diabetic drugs, namely, rosiglitazone
(ROSI) and metformin (MET) on some vascular and biochem-
ical alterations that associate experimentally-induced hyper-
glycaemia in rats. Hyperglycaemia was induced by a single
intraperitoneal (i.p.) injection of streptozotocin (STZ). Both
drugs were administered orally once per day for 14 consecutive
days and their effects were evaluated 24 h after the administra-
tion of the last dose. For the assessment of hyperglycaemia-in-
duced vascular changes, the responsiveness of the isolated
thoracic aortic rings towards various vasoactive agents
namely, norepinephrine (NE), acetylcholine (Ach), and sodium
nitroprusside (SNP) was tested. For the assessment of hyper-
glycaemia-induced biochemical changes, the blood levels of
some relevant biomarkers for oxidative stress and NO were
determined. Plasma lipid peroxides level (measured as mal-
ondialdehyde; MDA) and erythrocytic glutathione peroxidase
(GSH-Px) activity were taken as in vivo reliable indices for the
contribution of free radical generation and in turn, oxidative
stress in STZ-induced hyperglycaemia. Plasma nitrate/nitrite
level was used as a convenient marker for NO formation.
2. Materials and Methods
2.1. Drugs and chemicals
Rosiglitazone maleate (GlaxoSmithKlein Company, Egypt)
and metformin hydrochloride (Cid Company, Egypt) were used
in the present investigation. Both drugs were freshly prepared indistilledwater and given orally. The concentration of either drug
was adjusted so that each 100 g animal body weight received
0.5 ml, containing the required dose. Streptozotocin, acetylcho-
line perchlorate andN-(1-Naphthyl) ethylene-diamine dihydro-
chloride (NEDD) were purchased from Sigma–Aldrich, USA.
Norepinephrine hydrochloride, sodium nitroprusside, and sul-
phanilamide were purchased from Fluka (Italy), Oxford Labo-
ratory (India), and Merck (Germany), respectively. All other
chemicals were of the highest commercially available grade.
2.2. Animals
Adult male albino rats, weighing 180–250 g, were used in all
experiments of this study. They were obtained from the Ani-
mal House Colony of the National Research Center (Dokki,
Giza, Egypt), and were housed under conventional laboratory
conditions throughout the period of experimentation. The ani-
mals were fed a standard rat pellet diet and allowed free access
to water. The study was conducted in accordance with ethical
procedures and policies approved by the Animal Care and Use
Committee of National Research Center.
2.3. Induction of hyperglycaemia
Hyperglycaemia was induced by a single i.p. injection of STZ
(55 mg/kg).14 Brieﬂy, rats were weighed and injected with STZ
dissolved in a citrate buffer (0.1 M, pH 4.5). After 48 h blood
samples were withdrawn from the retro-orbital venous plexus
under light ether anaesthesia and the plasma was separated
by centrifugation for the determination of glucose level. Only
rats with plasma glucose levels more than 250 mg/dl were se-
lected and considered as hyperglycaemic animals that have
been subjected to further experimentation.
2.4. Experimental design
Hyperglycaemic rats were weighed and randomly allocated
into 3 groups (8–10 rats each). One group served as hypergly-
caemic control, while the other 2 groups were treated orally
with ROSI (0.5 mg/kg/day)15,16 and MET (150 mg/kg/day)17
for 14 consecutive days, respectively. Drug treatment was
started 48 h after STZ injection (time at which hyperglycaemia
was conﬁrmed). In addition, a universal normal group which
received only the citrate buffer (8–10 rats) was used. Twenty-
four hours after the last dose of either drug treatment, animals
were weighed and then sacriﬁced by cervical dislocation. Blood
was collected and prepared for the biochemical determination
of MDA and NO levels as well as GSH-Px activity. Rings from
isolated thoracic aortas were then prepared and suspended in
an organ bath to test their reactivity towards the selected vaso-
active agents, namely, NE, Ach, and SNP.
2.4.1. Assessment of vascular reactivity
The vascular reactivity towards NE as a vasoconstrictor, Ach
as an endothelium-dependent vasodilator, and SNP as an
endothelium-independent vasodilator was assessed using the
isolated aortic ring preparation described by Cocks et al.18
Brieﬂy, segments of thoracic aortas were rapidly placed in
warm Krebs’ solution and dissected free of surrounding tissue
before being cut into transverse rings of 3–5 mm length. An
aortic ring was mounted in 10 ml water jacketed automatic
Streptozotocin-induced vascular and biochemical changes in rats: Effects of rosiglitazone vs. metformin 133multi-chamber organ bath system (Model No. ML870B6/C,
Panlab, Spain) containing Krebs’ solution of the following
composition (g/l): NaCl 6.9, KCl 0.35, KH2PO4 0.16, MgSO4
7H2O 0.3, CaCl2 2H2O 0.37, NaHCO3 2.1, and glucose 1.05.
The organ bath solution was continuously aerated with carbo-
gen (a mixture of 95% O2 and 5% CO2) and its temperature
was kept at 37 C. The mounted aortic ring was suspended
horizontally between 2 hooks passed through its lumen, care
being taken not to injure the luminal surface. The bottom
hook was attached to a support leg while the upper one was
attached to a force–displacement transducer (Model No.
MLT0201, Panlab, Spain) connected to an ampliﬁer (Power-
Lab, AdInstruments Pty. Ltd.) which is connected to a com-
puter. The chart for windows (v 3.4) software was used to
record and elaborate data. The preparation was allowed to
equilibrate for about 2 h under a resting tension of 2 g during
that time any change in the resting tension was readjusted.
NE, Ach, and SNP were freshly prepared by dissolving
them in Kerbs’ solution. Serial dilutions of each vasoactive
agent were prepared such that cumulative additions to the bath
gave a ﬁnal bath concentration ranging from 109 M to
104 M. For testing the relaxant effect of Ach or SNP, pre-
contraction with NE was carried out ﬁrst with a concentration
that produces approximately 60–70% of the maximum con-
tractile response. Contractile responses to NE were expressed
as percentage of maximal response while relaxant responses
to the vasodilators Ach and SNP were expressed as percentage
relaxation of the pre-contraction value.
2.4.2. Assessment of biochemical parameters
From each 18 h food-deprived rat, 2 blood samples were with-
drawn from the retro-orbital venous plexus using heparinized
capillary tubes and collected into 2 tubes containing EDTA.
One blood sample was centrifuged at 3000 rpm for 10 min and
the plasma was obtained. An aliquot of the separated plasma
was then used for the determination of glucose level while the
rest was stored at 70 C for the subsequent determination of
MDA and NO levels. The other blood sample was centrifuged
at 3000 rpm for 10 min at 4 C using the cooling centrifuge
(Laborezentrifugen, 2k15, Sigma, Germany) and the plasma
was drawn off. Blood cells’ sediment was then washed once with
10 volumes of cold saline (0.9%w/v NaCl). Lysis of sedimented
erythrocytes was performed by adding 4 volumes of cold deion-
ized water to the estimated pellet volume. Centrifugation at
3000 rpm for 10 min at 4 C was then carried out and the resul-
tant clariﬁed erythrocyte lysate was collected and stored at
70 C for the subsequent determination of GSH-Px activity.
2.4.2.1. Determination of glucose level. Glucose level was deter-
mined as quinineamine using a test reagent kit (Stanbio, USA)
according to the method of Trinder.19 The absorbance was
measured at 510 nm and the results were expressed as mg/dl.
2.4.2.2. Determination of lipid peroxides level. Lipid peroxides
level was determined as thiobarbituric acid (TBA)-reactive sub-
stances using a test reagent kit (Biodiagnostic, Egypt) according
to the method of Ohkawa et al.20 The absorbance was measured
at 534 nm and the results were expressed as nmol/ml.2.4.2.3. Determination of NO level. The total amount of NO
was indirectly estimated in terms of its main metabolites,nitrate and nitrite by the Griess reaction using NEDD and
sulphanilamide as described by Miranda et al.21 after deprote-
inizing the sample with absolute ethanol. The absorbance
was measured at 540 nm and the results were expressed as
nmol/ml.
2.4.2.4. Determination of GSH-Px activity. GSH-Px activity
was determined by a kinetic assay at 37 C using a test reagent
kit (Biodiagnostic, Giza, Egypt) according to the method de-
scribed by Paglia and Valentine.22 The absorbance was mea-
sured at 340 nm and the results were expressed as mU/ml.
2.4.3. Assessment of body weight changes
Each rat was weighed individually twice, ﬁrst at the beginning
of the experiment (initial weight) and second 24 h after the
administration of the last dose of either drug (ﬁnal weight).
The difference in body weight of each rat was calculated and
expressed as percentage change according to the following:
%change inbodyweight ¼ finalweight  initialweight
initialweight
 1002.5. Statistical analysis
Data are expressed as means ± SEM. Statistical signiﬁcance
was taken as P< 0.05, using a one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparisons test
to judge the difference between various groups.
3. Results
3.1. Vascular reactivity experiments
3.1.1. Effect of ROSI and MET on NE-induced contractions
Cumulative concentrations of NE, starting from 109 M to
104 M, produced a concentration-dependent contraction of
aortic rings isolated from normal rats. A maximum contrac-
tion was achieved at a concentration of 105 M NE, reaching
about 98.12% ±0.58 of the maximal response. Aortic rings
isolated from hyperglycaemic rats (16 days after STZ adminis-
tration) showed an attenuation of the vascular responsiveness
towards almost all concentrations of NE, especially at concen-
trations from 109 M to 106 M, as compared to the respective
values of normal group. Oral treatment of hyperglycaemic rats
with either ROSI (0.5 mg/kg/day) or MET (150 mg/kg/day)
for 2 weeks tended to further decrease the vascular responsive-
ness of aortic rings as compared to the respective values of
hyperglycaemic-untreated group. The decreased responsive-
ness was, however, quite signiﬁcant at high concentrations of
NE starting from 106 M (Fig. 1a).
3.1.2. Effect of ROSI and MET on Ach-induced relaxations
Cumulative concentrations of Ach, starting from 109 M to
104 M, elicited a dose-dependent relaxation of aortic rings
isolated from normal rats (pre-contraction was achieved with
106 M of NE). A maximum relaxation was attained at a con-
centration of 104 M Ach, reaching about 89.40% ±5.62 of
the pre-contraction value. Aortic rings isolated from hypergly-
caemic rats (16 days after STZ administration) showed a
decrease of the vascular responsiveness towards almost all
Figure 1 Effect of rosiglitazone and metformin on NE-induced contractions (a), Ach-induced relaxations (b), and SNP-induced
relaxations (c) of aortic rings isolated from streptozotocin-treated rats. Rats were rendered hyperglycaemic by a single i.p. injection of
streptozotocin (STZ; 55 mg/kg). Rosiglitazone (ROSI; 0.5 mg/kg/day; p.o.) and metformin (MET; 150 mg/kg/day; p.o.) were
administered 48 h after STZ injection for 2 weeks. Aortas were isolated and suspended as rings (length, 3–5 mm) 24 h thereafter.
Relaxation was induced by applying cumulative concentrations on aortic rings pre-contracted with 106 M of NE. Results are expressed
as means ± SEM (n= 6–10). *Signiﬁcant difference from normal rats at P< 0.05. @Signiﬁcant difference from hyperglycaemic rats at
P< 0.05.
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normal group. A maximum relaxation of 31.71%±9.62 of the
pre-contraction value was achieved at a concentration of
104 M Ach. Oral treatment of hyperglycaemic rats with ROSI
(0.5 mg/kg/day) for 2 weeks showed an enhancement of the
vascular responsiveness of aortic rings towards almost all con-
centrations of Ach as compared to the respective values of
hyperglycaemic-untreated group. A maximum relaxation of
91.57% ±3.29 of the pre-contraction values was attained at
3 · 105 M Ach. A similar treatment of hyperglycaemic rats
with MET (150 mg/kg/day) restored the attenuated vascular
responsiveness of aortic rings towards almost all concentra-
tions of Ach. A maximum relaxation of 71.70%± 10.34 of
the pre-contraction values was attained at 104 M Ach
(Fig. 1b).
3.1.3. Effect of ROSI and MET on SNP-induced relaxations
Cumulative concentrations of SNP, starting from 109 M to
104 M, produced a concentration-dependent relaxation of
aortic rings isolated from normal rats (pre-contraction was
elicited with 106 M of NE). A maximum relaxation was
achieved at a concentration of 104 M SNP, reaching about
178.82%±17.28 of the pre-contraction value. Aortic rings iso-
lated from hyperglycaemic rats (16 days after STZ administra-
tion) showed an attenuated vascular responsiveness towards
SNP, as compared to the respective values of normal group,
especially towards high concentrations of SNP starting from
106 M. A maximum relaxation of 91.34% ±3.44 of the
pre-contraction value was attained at a concentration of
104 M SNP. Oral treatment of hyperglycaemic rats with
ROSI (0.5 mg/kg/day) for 2 weeks produced an enhancement
of the vasorelaxant effect towards SNP, as compared to the
normal group. A maximum relaxation of 272.35% ±19.51
of the pre-contraction value was attained at a concentration
of 3 · 105 M SNP. Similar treatment of hyperglycaemic rats
with MET (150 mg/kg/day) tended to restore the attenuated
vascular responsiveness towards SNP. A maximum relaxation
of 113.92% ±7.74 of the pre-contraction value was elicited at
a concentration of 104 M SNP (Fig. 1c).3.2. Biochemical parameters experiments
3.2.1. Effect of ROSI and MET on plasma glucose level
A single i.p. injection of STZ (55 mg/kg) produced an elevation
of plasma glucose level which was evidenced 48 h after admin-
istration. The elevation was found to be persistent during the
period of investigation and reached the average value of
376% of the normal one, 16 days after STZ administration.
Oral treatment of hyperglycaemic rats with either ROSI
(0.5 mg/kg/day) or MET (150 mg/kg/day) for 2 weeks suc-
ceeded to cause a decrease in the elevated plasma glucose level
reaching nearly the normal values (Table 1).
3.2.2. Effect of ROSI and MET on erythrocytic GSH-Px
activity
Induction of hyperglycaemia with a single i.p. injection of STZ
(55 mg/kg) was associated with a decreased erythrocytic GSH-
Px activity. The decreased activity reached about 41% of the
normal values, 16 days after STZ administration. Oral treat-
ment of hyperglycaemic rats with either ROSI (0.5 mg/kg/
day) or MET (150 mg/kg/day) for 2 weeks provoked an in-
crease in the decreased enzyme activity reaching about 71%
and 73% of the normal values, respectively (Table 1).
3.2.3. Effect of ROSI and MET on plasma MDA level
Induction of hyperglycaemia with a single i.p. injection of STZ
(55 mg/kg) was encountered with an elevated plasma MDA le-
vel. This elevation reached about 167% of the normal values,
16 days after STZ administration. Oral treatment of hypergly-
caemic rats with ROSI (0.5 mg/kg/day) for 2 weeks caused a
decrease in the elevated plasma MDA level reaching about
119% of the normal value. A similar treatment of hyperglycae-
mic rats with MET (150 mg/kg/day) did not show any signiﬁ-
cant change in the elevated plasma MDA level as compared to
the hyperglycaemic group (Table 1).
3.2.4. Effect of ROSI and MET on plasma NO level
Induction of hyperglycaemia with a single i.p. injection of STZ
(55 mg/kg) was accompanied by a decreased plasma NO level.
Table 1 Effect of rosiglitazone and metformin on blood glucose, MDA, and NO levels as well as GSH-Px activity of streptozotocin-
treated rats. Rats were rendered hyperglycaemic by a single i.p. injection of streptozotocin (STZ; 55 mg/kg). Rosiglitazone (ROSI;
0.5 mg/kg; p.o.) and metformin (MET; 150 mg/kg; p.o.) were administered for 2 weeks. Treatment with either drug was started 48 h
after STZ injection. Twenty-four hours after the last dose of either drug, blood samples from 18 h food-deprived animals were
withdrawn using heparinized capillary tubes and collected into tubes containing EDTA. Separated plasma was used for glucose, MDA,
and NO estimation while erythrocyte lysate was used for GSH-Px estimation. Results are expressed as means ± SEM (n= 6–10).
Groups Glucose (mg/dl) GSH-Px (mU/ml) MDA (nmol/ml) NO (nmol/ml)
Normal 114.05 ± 5.01 141.73 ± 15.53 6.40 ± 0.03 60.41 ± 2.04
Hyperglycaemic 429.00 ± 8.08* 58.36 ± 5.62* 10.75 ± 0.86* 22.30 ± 2.45*
Hyperglycaemic + ROSI 101.34 ± 10.47@ 101.16 ± 11.78@ 7.60 ± 0.65@ 43.49 ± 3.30*,@
Hyperglycaemic +MET 95.69 ± 2.33@ 103.75 ± 5.62@ 9.65 ± 0.98* 30.73 ± 1.67*
* Signiﬁcant difference from normal rats P< 0.05.
@ Signiﬁcant difference from hyperglycaemic rats P< 0.05.
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16 days after STZ administration. Oral treatment of hypergly-
caemic rats with ROSI (0.5 mg/kg/day) for 2 weeks caused an
elevation in the decreased plasma NO level reaching about
72% of the normal value. A similar treatment of hyperglycae-
mic rats with MET (150 mg/kg/day) did not affect the de-
creased plasma NO level as compared to the hyperglycaemic
group (Table 1).
3.3. Effect of ROSI and MET on body weight change
Induction of hyperglycaemia with a single i.p. injection of STZ
(55 mg/kg) was associated with a loss in body weight by an
average of about 26% of the normal values, 16 days after
administration of STZ. Oral treatment of hyperglycaemic rats
with either ROSI (0.5 mg/kg/day) or MET (150 mg/kg/day)
for 2 weeks decreased body weight loss and showed a gain
by about 2.55% and 2.8%, respectively (Fig. 2).4. Discussion
Results of the present study revealed that STZ-induced hyper-
glycaemia in rats was accompanied by some vascular andFigure 2 Effect of rosiglitazone and metformin on body weight of st
single i.p. injection of streptozotocin (STZ; 55 mg/kg). Rosiglitazone (R
administered for 2 weeks. Treatment with either drugwas started 48 h aft
of the experiment and 24 h after the last dose of either drug, the change in
means ± SEM (n= 6–10). *Signiﬁcant difference from normal rats P<biochemical changes. The vascular changes were evidenced
by alterations in the reactivity of isolated aortic rings towards
a vasoconstrictor as well as endothelium-dependent and -inde-
pendent vasodilators. The biochemical changes, on the other
hand, were evidenced by an increased level of plasma MDA
concomitantly with the decreased activity of erythrocytic
GSH-Px and level of plasma NO. STZ-induced hyperglyca-
emia was also encountered with a profound loss in body
weight. These ﬁndings were in accordance with previously
reported data.23–25
Aortic rings isolated from hyperglycaemic rats showed a de-
creased reactivity towardsNE, an a1-adrenoceptor agonist. Sev-
eralmechanisms are proposed to be implicated for such vascular
impairment, including non-enzymatic protein glycation, sorbi-
tol myoinositol changes, generation of ROS, and activation of
diacylglycerol protein kinaseCpathway.23 It is well documented
that hyperglycaemia that associates DM results in endothelial
cell damage leading to vascular reactivity changes. Previous
studies concernedwith the contractile response ofa1-adrenocep-
tor agonists showed, however, inconsistent results, while in
some increased reactivity was demonstrated26, in others de-
creased27 or unchanged responsiveness28 was shown. This dis-
crepancy has been related to the duration and/or the severity
of the induced hyperglycaemia.29reptozotocin-treated rats. Rats were rendered hyperglycaemic by a
OSI; 0.5 mg/kg; p.o.) and metformin (MET; 150 mg/kg; p.o.) were
er STZ injection. Each rat was weighed individually at the beginning
body weight was calculated as percentage. Results are expressed as
0.05. @Signiﬁcant difference from hyperglycaemic rats P< 0.05.
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either ROSI or MET for 2 weeks showed a further decrease in
the vascular responsiveness towards NE as compared to the
respective hyperglycaemic-untreated group. It has been ob-
served that ROSI is able to reduce BP in diabetic patients,30,31
hypertensive transgenic mice,32 spontaneously hypertensive
rats,33 and in Zucker fatty rats.34 ROSI may directly regulate
vessel tone and thus potentially contribute to the improved
BP.32 Moreover, it has been found that MET signiﬁcantly re-
duced the contractility towards the a1-adrenoceptor agonist,
phenylephrine and reduced the elevated BP in diabetic rats.17
Acetylcholine is a vasoactive substance that requires the
presence of endothelial cells to produce its relaxant effect on
the vasculature. It has been documented that this relaxation
is due to the release of NO from the vascular endothelium,
an effect which is absent in rubbed or denuded vessels.35 Re-
sults of the current study revealed that hyperglycaemic rats
showed a decreased vascular responsiveness towards Ach. It
has been previously reported that endothelium-dependent
relaxation response to Ach is impaired in diabetic rat aor-
ta.30,36 Furthermore, reduction in endothelium-dependent
relaxation is a common feature known to occur in the arteries
of diabetic animals.37 Many mechanisms were proposed for
the reduced Ach-induced NO-dependent vasodilatation in dia-
betic animals including decreased NO release and/or decreased
reactivity of vascular smooth muscle (VSM) to NO.38 More-
over, it has been proven that DM is associated with an increase
in oxidative stress, which causes endothelium damage due to
increased production of ROS. Damaged endothelium cannot
produce vasodilators such as NO with the possibility of
increasing the production of vasoconstrictors such as endothe-
lin-1.39
In the current study, treatment of hyperglycaemic rats with
either ROSI or MET for 2 weeks caused an enhancement of
the vascular responsiveness towards Ach as compared to the
respective hyperglycaemic-untreated group. This observation
was supported by Ryan and his colleagues31 who showed that
ROSI improves the endothelial-dependant relaxation of the
carotid artery in hypertensive transgenic mice. Furthermore,
histological evidence implies that leukocyte inﬁltration into
atherosclerotic or ischaemic tissues which are a marker of an
inﬂamed and dysfunctional endothelium is reduced with ROSI
treatment.30,40 Some authors attributed the beneﬁcial effects of
ROSI to its anti-oxidant property41 while others related it to
the reduction of the inﬂammatory response.42 On the other
hand, the improving effect of MET on Ach-induced vasorelax-
ation in diabetic rats has been suggested to be due to elevated
cyclic-GMP level which in turn leads to a decreased intracellu-
lar calcium level.17,43
Sodium nitroprusside exerts its relaxant effect on VSM cells
via a spontaneous release of NO, without the involvement of
vascular endothelium.44 Results of the current study revealed
that hyperglycaemic rats showed a decreased vascular respon-
siveness towards SNP and their treatment with ROSI for
2 weeks caused an enhancement of SNP-induced relaxation
even more than that of normal animals. This may be attributed
to its anti-oxidant property.41 It has been reported that the
drug has the ability to restore the relaxant action of insulin
in resistant arteries and thus preventing the development of
hypertension. ROSI was documented to improve aortic dia-
stolic function of insulin resistant-hypertensive rats, a mecha-
nism that might be associated with an increase in NO, adecrease in BP and serum insulin as well as an improvement
of insulin resistance.45 On the other hand, oral treatment with
MET for 2 weeks tended to restore the attenuated vascular
responsiveness towards SNP. This was in accordance with
other studies where the drug improved the microvascular func-
tion in type 2 diabetic model. This effect of MET has been re-
ported to be due to its direct effect on VSM.17
Oxidative stress and overexpression of NOS have been dis-
cussed as interrelated contributing factors in pancreatic b-cell
dysfunction and destruction associated with diabetic condi-
tions that lead to micro- and macrovascular complications.
Hyperglycaemia is considered one of the factors responsible
for the development of oxidative stress that results from en-
hanced formation of ROS by glucose auto-oxidation.46
Streptozotocin-induced hyperglycaemia selectively destroys
the islets of Langerhans by oxidant production and by produc-
ing inappropriate NO response.47,48 It has been previously
shown that toxic action of STZ is due to the generation of free
radicals49 which results in enhanced lipid peroxidation.50,51
In the present study, STZ-induced hyperglycaemia was
accompanied by an elevated plasma lipid peroxides level, sup-
pressed erythrocytic GSH-Px activity, and decreased plasma
NO level. It is well known that GSH-Px is among the endog-
enous scavenging anti-oxidant enzymes that remove the toxic
free radicals in vivo.52 GSH-Px is essential to reduce the levels
of ROS such as superoxide anion and hydrogen peroxide
which are considered to be the major causes of lipid peroxida-
tion. Erythrocytic GSH-Px, activity has been reported to be
lowered in diabetic conditions.24,53
Treatment of hyperglycaemic rats with ROSI for 2 weeks
showed a decrease in the elevated plasma MDA level and an
increase in the decreased erythrocytic GSH-Px activity which
might indicate that ROSI has a radical scavenging activity.41
MET treatment, on the other hand, provoked an increase in
GSH-Px activity but did not affect MDA level. This may be
probably because treatment of hyperglycaemia neutralizes oxi-
dative stress and thus restores anti-oxidant enzymatic activity
of GSH-Px. It has been previously reported that ROSI de-
creases blood MDA level while its level is not affected by
MET treatment.54 Other observations reported, however, that
MET reduced the oxidative stress in various animal models.55
Hyperglycaemic rats subjected to treatment with ROSI for
2 weeks caused an elevation of plasma NO level. This elevation
of NO has been previously reported to be due to stimulation of
NO synthesis and/or bioavailability in aortic endothelial cells
(via AMP-activated protein kinase)56,57 and in peripheral
skin.6 Treatment with MET, on the other hand, did not affect
plasma NO level as compared to hyperglycaemic group. It has
been assured that MET unlike ROSI does not activate AMP-
activated protein kinase and does not stimulate NO release in
human aortic endothelial cells.58,595. Conclusions
The ﬁndings of the current study revealed that oral treatment
with either ROSI or MET for 2 weeks exerted beneﬁcial effects
against some vascular and biochemical changes associated
with STZ-induced hyperglycaemia in rats. These beneﬁcial ef-
fects might be related to their ability to improve hyperglyca-
emia in addition to the anti-oxidant property of ROSI and
the direct effect of MET on VSM cells.
Streptozotocin-induced vascular and biochemical changes in rats: Effects of rosiglitazone vs. metformin 1376. Conﬂict of interest
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